Comparing CureVac (CVAC) and Its Competitors

CureVac (NASDAQ:CVAC) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare CureVac to similar companies based on the strength of its dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings and recommmendations for CureVac and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1	0	0	0	1.00
CureVac Competitors	9861	15274	45589	1597	2.54

As a group, “Biotechnology” companies have a potential upside of 120.47%. Given CureVac’s competitors stronger consensus rating and higher possible upside, analysts clearly believe CureVac has less favorable growth aspects than its competitors.

Profitability

This table compares CureVac and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
CureVac Competitors	-12,323.33%	-195.38%	-30.39%

Insider and Institutional Ownership

17.3% of CureVac shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 2.1% of CureVac shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares CureVac and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
CureVac	$70.74 million	$175.50 million	6.47
CureVac Competitors	$732.70 million	$12.23 million	-18.09

CureVac’s competitors have higher revenue, but lower earnings than CureVac. CureVac is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

CureVac has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, CureVac’s competitors have a beta of -1.84, indicating that their average stock price is 284% less volatile than the S&P 500.

Summary

CureVac competitors beat CureVac on 7 of the 13 factors compared.

CureVac Company Profile

CureVac is a biotechnology company founded in 2000 and headquartered in Tübingen, Germany. It focuses on messenger RNA (mRNA) technology, which uses genetic instructions to prompt cells to produce proteins that may help prevent or treat disease. The company has developed mRNA-based vaccine and therapeutic candidates for infectious diseases and cancer. Its programs have included COVID-19 vaccines and oncology research, and it has worked with pharmaceutical partners, including GSK, on mRNA vaccine development.